Summary
E-pharma is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €497,097 and a net result of €108,372. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 18% of 6,651 sector peers (NACE 64, financial year 2025). The company has been active since 2009 and the Belgian Official Gazette contains no insolvency or warning signals.
Directors
Board 1
Permanent representatives 1
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| AMBIXX BV |
|
| Erik VAN NUFFEL |
|
Owners and capital
Owners
1 ownerChain of control
- AMBIXX
- E-pharma
Highest known parent: AMBIXX. The sources do not say who stands above it.
Owners 1
- AMBIXXparentSourceaccounts AMBIXX 2025100%
According to the 2025 annual accounts of E-pharma and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.